Cormorant Asset Management, LP Avidity Biosciences, Inc. Transaction History
Cormorant Asset Management, LP
- $1.3 Billion
- Q2 2024
A detailed history of Cormorant Asset Management, LP transactions in Avidity Biosciences, Inc. stock. As of the latest transaction made, Cormorant Asset Management, LP holds 425,000 shares of RNA stock, worth $17.8 Million. This represents 1.34% of its overall portfolio holdings.
Number of Shares
425,000Holding current value
$17.8 Million% of portfolio
1.34%Shares
11 transactions
Others Institutions Holding RNA
# of Institutions
216Shares Held
95.8MCall Options Held
171KPut Options Held
196K-
Price T Rowe Associates Inc Baltimore, MD10.9MShares$457 Million0.05% of portfolio
-
Rtw Investments, LP New York, NY8.81MShares$369 Million6.01% of portfolio
-
Black Rock Inc. New York, NY8.62MShares$361 Million0.01% of portfolio
-
Avoro Capital Advisors LLC New York, NY6.51MShares$272 Million3.63% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.94MShares$249 Million0.0% of portfolio
About Avidity Biosciences, Inc.
- Ticker RNA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 52,127,000
- Market Cap $2.18B
- Description
- Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company's lead product candidate AOC 1001 is used for the treatment of myotonic dystrophy type 1, a rare monogenic...